SUPPLEMENTARY DATA

Supplementary Table 1. Number of insulin injections at Week 48 (study end; FAS).

No. of insulin injections per patient*	Premix (n=137) n (%)	Basal+ (n=130) n (%)
1 injection	48 (35)	59 (45)
2 injections	42 (31)	27 (21)
3 injections	43 (31)	30 (23)
4 injections	0	14 (11)

*4 (3%) patients could not be classified.

Supplementary Table 2. Insulin regimen at last Visit* (FAS).

	No of insulin injections n (%)	Before Breakfast	Before Lunch	Before Dinner
Premixed insulin analogue arm	1 injection (43/13.4%)			LM25
	1 injection (18/5.6%)		LM50	
	2 injections (48/15%)		LM50	LM25
	3 injections (36/11%)	LM25	LM50	LM25
	3 injections (7/2%)	LM50	LM50	LM25
Basal + insulin lispro arm	Glargine QD (80/25%)			
	Glargine+ 1Lispro (35/11%)**		X	X
	Glargine+ 2Lispro (31/10%)		X	X
	Glargine+ 3Lispro (15/5%)	X	X	X

* 8 (2.5%) patients could not be classified; **midday or evening.

SUPPLEMENTARY DATA

Supplementary Figure 1. Patient flow.

SUPPLEMENTARY DATA

Supplementary Figure 2. HbA1c LSmean (SEM) change from baseline at 48 weeks (FAS without LOCF).

FAS = full analysis set, HbA1c = hemoglobin A1c, LOCF = last observation carried forward, LSmean = least square mean, SEM = standard error of the mean

Supplementary Figure 3. Time to first hypoglycemia for final Premix treatments and final Basal+ treatments (safety set).

1. premixed insulin lispro (1 injection): LM50 (midday) or LM25 (evening)
2. premixed insulin lispro (2 injections): LM50 (midday) and LM25 (evening)
3. premixed insulin lispro (3 injections): LM25 (morning), LM50 (midday), LM25 (evening) or LM50 (morning), LM50 (midday), LM25 (evening)